Working… Menu

Treatment Strategy for Alcohol Use Disorders in Veterans With TBI (AUD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01342549
Recruitment Status : Completed
First Posted : April 27, 2011
Results First Posted : June 9, 2016
Last Update Posted : June 9, 2016
Information provided by (Responsible Party):
VA Office of Research and Development

Brief Summary:
The purpose of this research study is to understand the effectiveness of valproate (a common mood stabilizer) to further reduce alcohol misuse when given in addition to attending an alcohol rehabilitation program as well as the treatment of mood disorders or PTSD. The main goal of this project is to understand if people receiving valproate will have a better recovery than people receiving the standard treatment for alcohol dependence: naltrexone.

Condition or disease Intervention/treatment Phase
Alcohol Dependence Drug: Valproate Drug: Naltrexone Phase 3

Detailed Description:
Veterans are vulnerable to develop complex forms of addictive disorders characterized by the presence of traumatic brain injury and psychiatric conditions such as post-traumatic stress disorder and mood disturbances. Alcohol use disorders are frequently observed among veterans and exert a detrimental effect on community reintegration after deployment. Attending to this veteran health problem, the VA is devoting extraordinary efforts to develop adequate treatment strategies. In this study we will evaluate treatment outcomes and identify specific factors that influence alcohol use disorders treatment response in a VA Intensive Outpatient Program offering rehabilitation treatment to the growing number of veterans with alcohol use disorders. Cooperation between researchers and clinical staff will allow optimizing treatment strategies that enhance the recovery of veterans with alcohol use disorders.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 62 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treatment Strategy for Alcohol Use Disorders in Veterans With TBI
Study Start Date : September 2011
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Alcohol

Arm Intervention/treatment
Active Comparator: Arm 1
sodium valproate
Drug: Valproate
250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60 mg per kg per day. Usual dosage is between 1250mg to 2000mg per day
Other Name: Depakote ER

Active Comparator: Arm 2
Drug: Naltrexone
25mg per day, taken by mouth for 7 days, then 50mg per day
Other Name: Revia

Primary Outcome Measures :
  1. Time to Relapse to Heavy Drinking as Defined by Having 5 or More Drinks in a Sitting for Men and Will be Assessed Using the Time Line Follow Back for Recent Drinking Method. A Structured Questionnaire Will Review Alcohol Consumed on the Previous Week. [ Time Frame: 24 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Veterans attending alcohol use disorders rehabilitation treatment within the VA
  • Presence of a diagnosis of alcohol dependence according to DSM-IV
  • A history of heavy drinking
  • Absence of withdrawal symptoms

Exclusion Criteria:

  • Evidence of other substance abuse different from nicotine or cannabis (DSM-IV criteria) or by 2 consecutive positive urine drug screens
  • Unstable medical conditions such as severe heart disease, liver or renal failure or evidence of neoplasia.
  • Liver Enzymes (ALT, AST) serum levels >3 times the upper limit of normal
  • Unstable psychiatric conditions that requires treatment in a more structured setting (i.e. active SI, worsening psychotic symptoms or acute mania)
  • Diagnosis of schizophrenia or schizoaffective disorder
  • Requiring therapy with valproate or naltrexone or has a history of significant side effects from either study drug
  • Requiring therapy with topiramate, lamotrigine or carbamazepine
  • Requiring chronic treatment with opioid analgesics for refractory pain
  • Failed 3 previous intensive alcohol rehabilitation programs in the past 2 years
  • Females

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01342549

Layout table for location information
United States, Iowa
Iowa City VA Health Care System, Iowa City, IA
Iowa City, Iowa, United States, 52246-2208
United States, Texas
Michael E. DeBakey VA Medical Center, Houston, TX
Houston, Texas, United States, 77030
Sponsors and Collaborators
VA Office of Research and Development
Layout table for investigator information
Principal Investigator: Ricardo E Jorge, MD Michael E. DeBakey VA Medical Center, Houston, TX
Layout table for additonal information
Responsible Party: VA Office of Research and Development Identifier: NCT01342549    
Other Study ID Numbers: D7201-I
First Posted: April 27, 2011    Key Record Dates
Results First Posted: June 9, 2016
Last Update Posted: June 9, 2016
Last Verified: May 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by VA Office of Research and Development:
Alcohol Use Disorders
Traumatic Brain Injury
Mood and Anxiety Disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Alcohol Drinking
Drinking Behavior
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Valproic Acid
Alcohol Deterrents
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs